Showing results (21-30 of 338) with videos related to

Sort By:
Pageof 34
The Journal of Biological Chemistry|July 15, 1991
A congenitally abnormal fibrinogen (Vlissingen) with a 6-base deletion in the gamma-chain gene, causing defective calcium binding and impaired fibrin polymerizationJ Koopman, F Haverkate, E Briët, et al.
Advances in Experimental Medicine and Biology|January 1, 1990
Protein C and fibrinolysis: a link between coagulation and fibrinolysisN J de Fouw, F Haverkate, R M Bertina
Blood|August 1, 1986
Production and characterization of a monoclonal antibody reactive with a specific neoantigenic determinant (comprising B beta 54-118) in degradation products of fibrin and of fibrinogenP W Koppert, J Koopman, F Haverkate, et al.
Annals of the New York Academy of Sciences|July 20, 2001
Fibrinogen and its degradation products as thrombotic risk factorsG D Lowe, A Rumley
Acta Oto-Laryngologica. Supplementum|January 1, 1990
Whole blood viscosity and red cell filterability as factors in sensorineural hearing impairment in the elderlyS Gatehouse, G D Lowe
Biochimica Et Biophysica Acta|October 5, 1982
A fibrinogen fragment D (D intermediate) with calcium binding but without anticlotting propertiesW Nieuwenhuizen, M Voskuilen, A Vermond, et al.
Thrombosis and Haemostasis|April 25, 1989
The measurement of haemostatic factors in 16 European laboratories: quality assessment for the Multicentre ECAT Angina Pectoris Study. Report from the European Concerted Action on Thrombosis and Disabilities (ECAT)S G Thompson, F Duckert, F Haverkate, et al.
Annals of Epidemiology|July 1, 1992
The relationship between hemostatic tests and cardiovascular risk factors in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities (ECAT) Angina Pectoris GroupF Haverkate, S G Thompson, J C van de Loo
American Journal of Clinical Pathology|December 1, 1975
Fibrinolytic activity in aneurysmal bone cystsD J Ruiter, J Lindeman, F Haverkate, et al.
Thrombosis Research|August 1, 1985
Protraction of whole blood and plasma clot lysis in patients with high levels of an inhibitor of tissue-type plasminogen activatorE J Brommer, A L Boks, J Koopman, et al.
Pageof 34